La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Embla Medical hf Gestione

Gestione criteri di controllo 3/4

Embla Medical hf's Il CEO è Sveinn Solvason, nominato in Apr2022, e ha un mandato di 2.33 anni. la retribuzione annua totale è $ 1.18M, composta da 48.8% di stipendio e 51.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.016% delle azioni della società, per un valore di DKK 2.11M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 15.6 anni.

Informazioni chiave

Sveinn Solvason

Amministratore delegato

US$1.2m

Compenso totale

Percentuale dello stipendio del CEO	48.8%
Mandato del CEO	2.4yrs
Proprietà del CEO	0.02%
Durata media del management	2.4yrs
Durata media del Consiglio di amministrazione	15.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Aug 22

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 26

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Jul 17

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

May 14

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 26

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

Dec 22

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Dec 07

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Sep 21

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Sep 02

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Aug 16

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Jun 16

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Jun 01

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

May 08

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Feb 22

Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report

Feb 03

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Nov 25

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Oct 17

Is Össur hf (CPH:OSSR) A Risky Investment?

Sep 28

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Aug 21

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Jul 11

Here's Why Össur hf (CPH:OSSR) Can Manage Its Debt Responsibly

May 28

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

May 07

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Mar 25

We Think The Compensation For Össur hf.'s (CPH:OSSR) CEO Looks About Right

Mar 02

We Think Össur hf (CPH:OSSR) Can Stay On Top Of Its Debt

Feb 22

Does The Market Have A Low Tolerance For Össur hf.'s (CPH:OSSR) Mixed Fundamentals?

Feb 09

What Kind Of Shareholders Own Össur hf. (CPH:OSSR)?

Jan 26

Össur hf (CPH:OSSR) Shareholders Have Enjoyed An Impressive 115% Share Price Gain

Jan 08

We're Watching These Trends At Össur hf (CPH:OSSR)

Dec 21

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Sveinn Solvason rispetto agli utili di Embla Medical hf?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	US$61m
Mar 31 2024	n/a	n/a	US$57m
Dec 31 2023	US$1m	US$576k	US$58m
Sep 30 2023	n/a	n/a	US$52m
Jun 30 2023	n/a	n/a	US$45m
Mar 31 2023	n/a	n/a	US$43m
Dec 31 2022	US$780k	US$409k	US$43m

Compensazione vs Mercato: La retribuzione totale di Sveinn ($USD 1.18M ) è circa la media per le aziende di dimensioni simili nel mercato Danish ($USD 1.50M ).

Compensazione vs guadagni: La retribuzione di Sveinn è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Sveinn Solvason (46 yo)

2.4yrs

Mandato

US$1,180,000

Compensazione

Mr. Sveinn Solvason had been Chief Financial Officer of Embla Medical hf. (formerly known as ssur hf.) since May 2013 until April 1, 2022 and serves as its President & CEO since April 1, 2022.Mr. Solvaso...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Sveinn Solvason	President & CEO	2.4yrs	US$1.18m	0.016% $ 2.1m
Ossur Kristinsson	Founder	no data	US$25.00k	Nessun dato
Gudny Sveinsdottir	Chief Financial Officer	2yrs	Nessun dato	Nessun dato
Lukas Marklin	Chief Operating Officer	1.3yrs	Nessun dato	Nessun dato
Edda Luovigsdottir	Investor Relations Director	no data	Nessun dato	Nessun dato
Margret Fridriksdottir	Executive Vice President of People	no data	US$242.00k	0.0083% $ 1.1m
Olafur Gylfason	Chief Commercial Officer	no data	US$600.00k	0.0030% $ 394.5k
Gudjon Karason	Executive Vice President of EMEA & APAC	6.8yrs	Nessun dato	0.023% $ 3.0m
Christian Robinson	President of Americas	no data	Nessun dato	0.0031% $ 406.3k
Hildur Einarsdottir	Executive Vice President of Research & Development	2.4yrs	Nessun dato	0.00014% $ 18.4k

2.4yrs

Durata media

50yo

Età media

Gestione esperta: Il team dirigenziale di EMBLA è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Niels Jacobsen	Chairman of the Board	19.7yrs	US$108.00k	0.048% $ 6.3m
Svafa Gronfeldt	Vice Chairman of the Board	16.7yrs	US$72.00k	Nessun dato
Gudbjorg Eggertsdottir	Independent Director	11.5yrs	US$43.00k	0.0062% $ 810.0k
Arne Nielsen	Director	15.7yrs	US$50.00k	Nessun dato
Alberto Esquenazi	Independent Director	3.5yrs	US$43.00k	Nessun dato

15.7yrs

Durata media

67yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di EMBLA è composto da personale esperto e esperto (durata media dell'incarico 15.6 anni).

Embla Medical hf Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Össur hf., Annual General Meeting, Mar 12, 2025

Össur hf. Announces Executive Changes

Less than half of directors are independent

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Less than half of directors are independent

Recent updates

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

New minor risk - Financial position

A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Investor sentiment improves as stock rises 15%

Full year 2023 earnings: EPS misses analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2024

Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Össur hf., Annual General Meeting, Mar 12, 2025

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Third quarter 2023 earnings released: EPS: US$0.033 (vs US$0.016 in 3Q 2022)

Össur hf. Reaffirms Financial Guidance for the Year 2023

A Look At The Fair Value Of Össur hf. (CPH:OSSR)

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Second quarter 2023 earnings: EPS misses analyst expectations

Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Össur hf. Announces Executive Changes

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Consensus EPS estimates fall by 12%

Full year 2022 earnings: Revenues in line with analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2023

A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2023 Results on Apr 25, 2023

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Less than half of directors are independent

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings released: EPS: US$0.016 (vs US$0.041 in 3Q 2021)

Investor sentiment improved over the past week

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Össur hf. (CPSE:OSSR) acquired Naked Prosthetics.

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Second quarter 2022 earnings released: EPS: US$0.034 (vs US$0.046 in 2Q 2021)

Price target decreased to kr.42.00

Össur hf. Revises Earnings Guidance for the Year 2022

Össur hf. Reports Preliminary Earnings Results for the Second Quarter and First Half of 2022

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Price target decreased to kr.43.70

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Now 22% undervalued after recent price drop

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

Now 20% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Össur Hf. Announces New R&D Leadership

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Össur Launches New POWER KNEE

Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report

Full year 2021 earnings: EPS misses analyst expectations

Össur hf. Announces Sales Guidance for the Full Year 2022

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.035 in 3Q 2020)

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)